While we wait for an effective vaccine against SARS-CoV-2, the influenza and Measles-Mumps-Rubella vaccine with proven safety and efficacy profile can a play critical role in reducing the healthcare burden. First, an increase in the coverage of influenza and Measles-Mumps-Rubella vaccines will decrease the number of cases and the need for hospitalisations for severe illnesses due to these diseases. It will, thereby, reduce the burden on healthcare providers and facilities, which will be particularly crucial in resource-poor settings in making the scarce resources (e.g. hospital beds) allocated to those who need them the most. Second, live attenuated vaccines such as Measles-Mumps-Rubella and Bacillus Calmette-Guerin have been reported to provide non-specific protection against lethal infections including pneumonia and sepsis, especially in low-income settings. Third, infection with measles has been shown to increase children's susceptibility to other infections by reducing the immune system's memory against other pathogens including the influenza virus. Therefore, infection with measles may also increase the susceptibility to SARS-CoV-2 even though it is yet to be empirically tested. Therefore, as we wait for a successful vaccine for COVID-19, we can minimise winter pressures on health systems and societies by maximising the uptake of influenza and Measles-Mumps-Rubella vaccines (and potentially Bacillus Calmette-Guerin vaccines, especially in tuberculosis-endemic areas).